StockNews.AI
ICAD
StockNews.AI
167 days

iCAD and RamSoft Announce Partnership to Deliver ProFound® AI-Powered Mammography Solutions Across North America

1. iCAD partners with RamSoft for AI cancer detection solutions. 2. ProFound AI Breast Health Suite improves diagnostic efficiency and patient care. 3. Integration targets over 750 healthcare sites in North America. 4. AI adoption addresses 20-40% undetected breast cancers. 5. iCAD's technology enhances workflow and early cancer detection.

11m saved
Insight
Article

FAQ

Why Bullish?

The strategic partnership with RamSoft significantly broadens ICAD's market access and utilization of its AI technology in imaging centers, predicted to enhance sales and improve patient outcomes. Historically, partnerships that integrate technology into larger networks subsequently lead to greater market penetration and financial performance.

How important is it?

This partnership presents a significant business development opportunity for ICAD by expanding access to their AI technology, which is essential for increasing revenue potential. The strategic nature of the agreement with an established market player like RamSoft emphasizes its importance.

Why Long Term?

The effects of this partnership will likely unfold over time as RamSoft integrates iCAD's solutions into its established networks, thereby increasing usage and driving revenue growth over the coming quarters and years. Previous similar collaborations in healthcare have shown gradual but exponential adoption curves.

Related Companies

RAMSFMDGSBAX
March 05, 2025 14:04 ET  | Source: iCAD, Inc. NASHUA, N.H. and TORONTO, March 05, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, and RamSoft®, a global leader in cloud-based RIS/PACS radiology solutions for imaging centers and providers, today announced a new strategic commercial preferred distributor and integration partnership across the US and Canada. With over 750 sites and thousands of healthcare providers worldwide utilizing RamSoft’s solutions, this collaboration brings iCAD’s ProFound AI® Breast Health Suite directly into imaging centers, enhancing workflow efficiency, increasing diagnostic confidence, and improving patient care, beginning within the platforms they already use. "iCAD’s partnership with RamSoft marks an important step in expanding access to AI-powered breast health solutions across North America," said Dana Brown, President and CEO of iCAD, Inc. "By integrating the ProFound Breast Health Suite into RamSoft’s leading RIS/PACS platform, we are equipping radiologists with the tools they need to enhance early detection and improve patient outcomes." "RamSoft is committed to delivering innovative solutions that streamline radiology workflows and improve diagnostic accuracy," said Vijay Ramanathan, CEO and Co-Founder of RamSoft. "Our collaboration with iCAD allows us to provide an advanced AI-powered mammography solution that enhances efficiency and enables better patient care. The first organization that will jointly be incorporating ProFound AI Breast Health Suite via the RamSoft PowerServer platform is Mammolink." "At Mammolink, our mission is to make high-quality breast cancer screening more accessible," said Dr. Ryan Polselli, Radiologist and Founder of Mammolink, a leading provider of 3D mammography and diagnostic ultrasound imaging services. "Integrating ProFound AI into our workflow via RamSoft’s PowerServer technology will allow us to deliver faster and more accurate results to the women who rely on us for timely, life-saving screenings." With 20-40% of breast cancers remaining undetected by traditional screening mammography, healthcare institutions are increasingly adopting AI to improve diagnostic accuracy and operational efficiency. The ProFound AI Breast Health Suite is designed to address these challenges by offering a comprehensive AI-powered mammography solutions. ProFound AI analyzes each mammogram with high sensitivity, identifying suspicious areas earlier and providing radiologists with crucial insights to enhance accuracy and efficiency in screenings. By seamlessly integrating into RamSoft’s imaging platform, ProFound AI empowers radiologists with real-time, data-driven decision support, ultimately improving patient outcomes and operational workflows. iCAD’s ProFound AI Breast Health Suite will be integrated into the PowerServer cloud-based RIS/PACS platform designed to provide unmatched functionality, flexibility, and data management—even in the most demanding imaging environments. PowerServer is an advanced solution that is FDA 510(k) cleared and IHE mammo profile compliant, ensuring regulatory compliance and high standards of quality. It features customizable layouts, allowing radiologists to seamlessly navigate viewing steps for enhanced efficiency. Additionally, the viewer supports MG CAD Markers, aiding in precise interpretation, and includes digital breast tomosynthesis (DBT) support, enabling advanced imaging analysis. By unifying access to all related breast imaging studies within a single worklist, the PowerServer platform streamlines workflow, reduces redundant tasks, and improves overall diagnostic efficiency. iCAD and RamSoft will be attending HIMSS 2025, from Monday, March 3-6, 2025 in the Venetian Convention & Expo Center, Las Vegas, NV. RamSoft will demonstrate its full line of cloud-based RIS/PACS software solutions including its newest AI-driven radiological solutions and its new patient portal, Blume, in booth #5039. About RamSoft®RamSoft is a global provider of innovative cloud-based radiology software solutions for imaging centers, radiology departments, and teleradiology providers. PowerServer™, utilized by over 750 sites and thousands of customers worldwide, offers a flexible, scalable design enabling imaging operations of all sizes to leverage comprehensive cloud-based RIS (Radiology Information System)/PACS (Picture Archiving and Communication System) capabilities. RamSoft’s latest offering, OmegaAI®, is a cloud-native AI-driven platform delivering rapid, secure, and robust RIS and PACS capabilities that are completely zero footprint, powered by Microsoft Azure. Additionally, Blume™ - Patient Portal allows patients to access, store and share their diagnostic imaging studies with referring physicians, family members and for personal record. About MammolinkMammoLink® is improving breast cancer screening by changing the relationship between doctors, radiologists, and patients to make mammograms more accessible. Operating 5 state-of-the-art mobile mammography buses, Mammolink provides accessible 3D mammography to women across Florida with guaranteed results provided within 24 hours. For more information, please visit www.MammoLink.com. About iCAD, Inc.iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven deep learning solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., USA, iCAD’s industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly 30% being tomosynthesis. *ProFound Detection V4 is FDA Cleared. ProFound AI V3 and PowerLook Density Assessment are FDA Cleared, CE Marked, and Health Canada Licensed. ProFound AI Risk is CE Marked and Health Canada Licensed, is not FDA Cleared, and is only available in the US for investigational use. Products may not be available in all geographies. For more information, including the latest in regulatory clearances, please visit www.icadmed.com. Forward-Looking StatementsCertain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company’s products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of the Company’s products, and future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at https://www.icadmed.com and on the SEC’s website at http://www.sec.gov. CONTACTSiCAD Media Inquiries:pr@icadmed.com iCAD Investor Inquiries:John Nesbett/Rosalyn ChristianIMS Investor Relationsicad@imsinvestorrelations.com RamSoft Inquiries: Rob SandlerChief Marketing Officer+1 647-361-4516rob.sandler@ramsoft.com

Related News